Clearline Capital’s Achieve Life Sciences ACHV Stock Holding History

Clearline Capital’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-451,219	Closed	-$1.42M	–	106
2025 Q3	$1.42M	Sell	451,219 -875,040	-66%	-$2.4M	0.07%	88
2025 Q2	$3M	Buy	+1,326,259	New	+$3.78M	0.11%	78
2023 Q1	–	Sell	-27,156	Closed	-$66.5K	–	109
2022 Q4	$66.5K	Sell	27,156 -92,938	-77%	-$238K	0.01%	119
2022 Q3	$396K	Hold	120,094	–	–	0.05%	120
2022 Q2	$586K	Hold	120,094	–	–	0.08%	106
2022 Q1	$909K	Sell	120,094 -1,918	-2%	-$14.3K	0.1%	93
2021 Q4	$949K	Hold	122,012	–	–	0.1%	96
2021 Q3	$1.04M	Buy	122,012 +200	+0.2%	+$1.57K	0.1%	99
2021 Q2	$1.09M	Buy	+121,812	New	+$1.16M	0.16%	86

Other funds holding ACHV

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clearline Capital's ACHV Position: Q4 2025 in Review

Clearline Capital sold out of Achieve Life Sciences (ACHV) in Q4 2025, closing a stake of 451,219 shares — an estimated $1.42M sold.

Clearline Capital first reported a position in ACHV in Q2 2021 and held it in 9 quarters. The position peaked at $3M in Q2 2025. 77 funds tracked by Wall St. Rank hold ACHV as of Q4 2025.

Clearline Capital reported no remaining Achieve Life Sciences position as of Q4 2025 after selling out during the quarter.
Clearline Capital sold 451,219 Achieve Life Sciences shares in Q4 2025, an estimated $1.42M.
Clearline Capital first reported a position in Achieve Life Sciences in Q2 2021 and held it in 9 quarters.
Clearline Capital's Achieve Life Sciences position peaked at $3M in Q2 2025.
77 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q4 2025.

Based on Clearline Capital's 13F filing for Q4 2025, filed 17 Feb 2026.